Please login to the form below
cancer
This page shows the latest cancer news and features for those working in and with pharma, biotech and healthcare.
Innovent gears up for PD-1 inhibitor launch in China
Chinese biotech Innovent is in the final stages of preparing to launch its cancer immunotherapy Tyvyt in its home market. ... BMS’ Opdivo (nivolumab) was cleared in China for previously-treated non-small cell lung cancer (NSCLC) in June 2018, while
Latest news
-
Amgen, Servier start second phase 3 trial of heart failure hope
Treatment is one of few in underserved area
-
More good news, and some bad, for Merck’s Keytruda
press its already-dominant position in non-small cell lung cancer (NSCLC), the more common form. ... for head and neck cancer both as a monotherapy and in combination with chemotherapy.
-
Greater Manchester backs move to outcome-based payment
Now England’s leading devolved health region, Greater Manchester, has teamed up with charity Cancer Research UK to look at how to adopt the new approach. ... We look forward to working with government, NHS England, industry and patients to make this
-
Merck & Co to buy IO specialists Immune Design for $300m
The race is now on to find the next generation IO mechanism which could unlock greater benefits for patients across a range of diseases, and not just cancer. ... The company's technologies, GLAAS and ZVex, are engineered to activate the immune system's
-
Xencor’s Novartis-partnered bispecific on hold after patient deaths
It is coupled with a second tumour-associated domain designed to bring T cells into contact with the cancer cells – CD123 in the case of XmAb14045 and CD20 for XmAb13676.
More from news
Approximately 611 fully matching, plus 2,700 partially matching documents found.
Latest Intelligence
-
Cell and gene therapy
patient.”. Althoff cites Novartis’ Kymriah (tisagenlecleucel), a blood cancer cell therapy approved in Europe and the US last year, as an example of the differing manufacturing costs.
-
2019: CRISPR and therapeutic gene editing comes of age
hope was that - without the brake of PD-1 – the edited cells would attack and defeat the cancer. ... The work was reported in the journal Nature and, since then, another Chinese group has tested a similar approach in head and neck cancer.
-
Cutting through the noise: CRISPR
Luke Gilbert, assistant professor in the Department of Urology, the Helen Diller Family Comprehensive Cancer Center and the IGI at University of California, San Francisco, explains how the CRISPR-focused collaboration ... In normal development there’s
-
Immuno-oncology in 2019: the rapid evolution continues
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.
-
Drug launches to watch in 2019
These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... 1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H).
More from intelligence
Approximately 8 fully matching, plus 261 partially matching documents found.
Latest appointments
-
New hires at Ferring, Flexion and Immunocore
It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;
-
New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics
He started his career with Eurand in Italy, and since 2011 he has worked for Helsinn Healthcare, a cancer care company.
-
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team
There he oversaw the oncology-focused company's launch in the region, as well as the launch and UK reimbursement of its PARP inhibitor in recurrent ovarian cancer.
-
BMS appoints new commercial leader, Davies joins Eisai and more
Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... class new treatments for cancer patients and to help transform the company into a world-class
More from appointments
Approximately 5 fully matching, plus 201 partially matching documents found.
Latest from PMHub
-
International Childhood Cancer Day 2019
We've pulled together an infographic to show just what we mean with data c/o Cancer Research UK (CRUK) and a great initiative by Beads of Courage, Inc. ... There's still more to do, so show your support for a day when there is No More Pain and No More
-
Portable Cancer Screen Devices Market Technology Growth and Opportunities 2018 - 2028
The portable cancer screen devices are less expensive as compared to the mammography and X-rays. ... The portable cancer screen devices can be used at regular preventive health check-ups.
-
Clinical Trials Market to Witness Robust Expansion throughout the Forecast 2018 - 2028
for discovering and developing immuno-oncology therapies. This collaboration will mainly help in discovering new cancer targets using proprietary FIND-IO platform of NextCure, Inc. ... Cancer. Circulatory diseases. Autoimmune diseases. Ophthalmology.
-
Airotar Handpiece Market Value Share, Supply Demand, share and Value Chain 2018 - 2028
Growing dental disorder, tooth loss, oral cancer, gum disorder are boosting the number of dental procedures.
-
Intravenous Solution Compounders Market Volume Analysis, Segments, Value Share and Key Trends 2018 - 2028
The added advantages of intravenous solution compounders in reducing the risk of injectables medication errors specifically in cancer chemotherapy preparation is anticipated to fuel the market for intravenous solution compounders market.
More from PMHub
Approximately 35 fully matching, plus 161 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Project Manager/ Account Manager
-
Salary TBC
-
Digital Account Director
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- Drug launches to watch in 2019
- Welcome to the Communique Awards - Communiqué Awards 2018
- ‘Inflexible’ NICE blocking access to rare disease drugs
- 2019: CRISPR and therapeutic gene editing comes of age
- GW Pharma's cannabis-based medicine to be tested in dementia
- More good news, and some bad, for Merck’s Keytruda
- BioMarin prepares for haemophilia A gene therapy data readout, filing
- Innovent gears up for PD-1 inhibitor launch in China
- NICE knocks back BioMarin’s Batten disease drug
- Amgen, Servier start second phase 3 trial of heart failure hope
- The importance of co-creation with patients
- McCann Health's next challenge: creative differentiation
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- The importance of co-creation with patients
- Overcoming the barriers...
- Three billboards on the road to multichannel
- Chris Ross examines the trends driving multichannel communication in 2019...
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
